Announcement

24 Feb 2021

At the beginning of 2020, the COVID-19 Pandemic resulted in restrictions which made on-site monitoring of clinical trial data and documents more challenging due to safety and social distancing restrictions. These restrictions meant alternative ways of monitoring clinical trials needed to be explored and implemented to ensure data integrity and patient safety on clinical trials.

24 Feb 2021

ECMC Quinquennial Review 12-month delay

The ECMC Network quinquennial review process has been delayed for 12-months, due to the impact of the pandemic on the ECMC Network sites. 

The current 5- year ECMC funding period (2017 – 2022) is due to end in March 2022. A quinquennial review process was scheduled to run between March and October this year to award funding for the 4th ECMC quinquennium (2022 – 2027). However, all sites in the network have been seriously impacted by the current wave of the Covid-19 pandemic.  

09 Dec 2020

Read recent updates from the Advanced & Cell Therapies team led by Professor Fiona Thistlethwaite and about the recent appointment of Dr Emma Searle to the Haematology team within the Manchester ECMC

09 Dec 2020

Read about the ACCEPT (a phase Ib/II) and ProCAID (placebo controlled randomised phase II) trials taking place at Southampton ECMC

09 Dec 2020

Biospecific antibodies are showing promising activity in early phase trials in relapsed/refractory Non-Hodgkin lymphoma (NHL), including patients that have received prior CAR-T therapies.

09 Dec 2020

Two trials from the Trials Acceleration Programme (TAP) will be opening across the UK - VICTOR and PROMise

09 Dec 2020

Researchers in the University of Sheffield Department of Oncology and Metabolism have formed a new university spinout company (Modulus Oncology) with experienced drug development entrepreneurs Dr Clare Wareing and Dr Alan Wise from Edinburgh-based bioincubator company Cumulus Oncology.

ECMC Logo
09 Dec 2020

Researchers from the University of Cambridge and Cold Spring Harbour Laboratory (CSHL) have completed an early phase clinical trial of a drug called plerixafor showing that it induces an integrated immune response in the tumours of patients with cancer types that do not usually respond to immunotherapy.

ECMC Logo
09 Dec 2020

The teams from ECMC North delivered successfully their first on-line educational event on October 19th 2020. We have now moved to developing the content for the ECMC COVID-19 Community Hub, a curated on-line platform to build on the learnings from the workshops held in October.

27 Nov 2020

The teams from ECMC North successfullly delivered their first online educational event on 19 October 2020. We have now moved to developing the content for the ECMC COVID-19 Community Hub, a curated online platform to build on the learnings from the workshops held in October.

Pages